Roche may lose $240 million contract in Russia to Biocad biosimilar

Roche may lose $240 million contract in Russia to Biocad biosimilar


Swiss drug major Roche may lose an important $240 million contract in Russia for the supply of its anti-cancer…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRegulationrituximabRoche

Biocad enters deal for exporting rituximab biosimilar to Turkey


Biocad, one of Russia's leading biotechnology companies, has signed a definitive agreement on the export…

BiocadBiotechnologyEuropeGenericsKocak FarmaLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRoche

Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab


Germany’s Stada Arzneimittel (SAZ: GR) and Hungarian group Gedeon Richter (BDP: RICHTER) have signed…

BiotechnologyGedeon RichterGenericsHerceptinLicensingMabTheraMarkets & MarketingOncologyRituxanrituximabRocheSTADA Arzneimitteltrastuzumab

GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019


Driven primarily by the launch and uptake of Human Genome Sciences and GlaxoSmithKline's Benlysta (belimumab),…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMabTheraMarkets & MarketingPharmaceuticalRituxan

Back to top